The Hindu Business Line : Aurobindo gets USFDA nod for AIDS drug

AUROBINDO Pharma Ltd has announced that it has received the approval of the United States Food and Drug Administration (USFDA) for Lamivudine, a key anti-retroviral (ARV) in the treatment of AIDS.

The company said the development enables it to participate in the President's Emergency Plan for Aids Relief (PEPFAR), an initiative of the US Government.

The company manufactures both active pharmaceutical ingredient (API) and formulation for Lamivudine.

It is participating in PEPFAR programme, wherein around $15 billion were earmarked for the five-year programme including around $1 billion per year for medicines.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Jurong to build township at Rushikonda

Aurobindo gets USFDA nod for AIDS drug

GMR may exit ING Vysya Life

Thirumalai Chem hikes prices of two products

Indian Potash to tap Lankan market

Mukesh, Anil agree on 5-yr `non-compete' clause
Settlement expected `any time'

Visaka Ind plans FCCB issue to fund expansion

SEBI cannot be sole regulator for cos accessing market: Irani panel
`Concern over regulatory overlap misplaced'

Sami Labs eyes overseas acquisitions

Pergo launches design centre in Kochi

Praj Ind board okays 1:1 bonus issue, stock split

ITC board recommends share split, 1:2 bonus

Everest eyes Rs 500-cr revenue in 4 years

SAIL draws up Rs 400-cr investment plans for DSP

GM plans to capture 10 pc market share by 2010 — Launch of small cars on cards